mesalamine has been researched along with Colorectal Cancer in 131 studies
Mesalamine: An anti-inflammatory agent, structurally related to the SALICYLATES, which is active in INFLAMMATORY BOWEL DISEASE. It is considered to be the active moiety of SULPHASALAZINE. (From Martindale, The Extra Pharmacopoeia, 30th ed)
mesalamine : A monohydroxybenzoic acid that is salicylic acid substituted by an amino group at the 5-position.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Evaluate factors influencing risk of colorectal cancer development in inflammatory bowel disease patients." | 5.36 | Mesalamine protects against colorectal cancer in inflammatory bowel disease. ( Pai, C; Sharif, O; Silverman, AL; Tang, J, 2010) |
| "The role of 5-aminosalicylic acid (5-ASA or mesalamine) in the prevention of colorectal cancer in ulcerative colitis (UC) patients was reported, but the effect on molecular targets in UC colon mucosa is unknown." | 3.91 | Effect of Long-Term Mesalamine Therapy on Cancer-Associated Gene Expression in Colonic Mucosa of Patients with Ulcerative Colitis. ( Alvarez, J; Amenta, PS; Bajpai, M; Cheng, J; Das, KK; Das, KM; Geng, X; Gorin, S; Minacapelli, CD; Poplin, E; Seril, DN; Van Gurp, J, 2019) |
| "Balsalazide is a colon-specific prodrug of 5-aminosalicylate that is associated with a reduced risk of colon cancer in patients with ulcerative colitis." | 3.85 | Combined Parthenolide and Balsalazide Have Enhanced Antitumor Efficacy Through Blockade of NF-κB Activation. ( Jeong, HJ; Kim, EM; Kim, IH; Kim, SH; Kim, SL; Kim, SW; Kim, YN; Lee, SO; Lee, ST; Liu, YC; Park, YR; Seo, SY, 2017) |
| "Some studies have suggested that mesalamine can prevent the development of colorectal cancer in patients with ulcerative colitis (UC)." | 3.74 | Progression to colorectal neoplasia in ulcerative colitis: effect of mesalamine. ( Bodian, C; Croog, V; Harpaz, N; Hossain, S; Itzkowitz, S; Kornbluth, A; Ullman, T, 2008) |
| " Other data collected included history of primary sclerosing cholangitis, family history of colorectal cancer, and smoking and drug history (mesalamine 5-aminosalicylic acid, azathioprine, and folate)." | 3.72 | Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis. ( Forbes, A; Kamm, M; Price, A; Rumbles, S; Rutter, M; Saunders, B; Schofield, G; Talbot, I; Wilkinson, K; Williams, C, 2004) |
| " Epidemiologic studies suggest that long-term use of non-steroidal anti-inflammatory drugs (NSAIDs), including mesalazine, has beneficial effects on colitis-associated colorectal cancer." | 3.01 | Molecular Mechanisms of the Antitumor Effects of Mesalazine and Its Preventive Potential in Colorectal Cancer. ( Madej, M; Strzalka-Mrozik, B; Słoka, J, 2023) |
| "The risk of colorectal cancer after 20 years of disease duration is 4." | 3.01 | Ulcerative Colitis in Adults: A Review. ( Gros, B; Kaplan, GG, 2023) |
| "Patients with colorectal cancer were asked to take mesalazine enemas for 14 days." | 2.69 | Mesalazine-induced apoptosis of colorectal cancer: on the verge of a new chemopreventive era? ( Bus, PJ; Geldof, H; Griffioen, G; Lamers, CB; Nagtegaal, ID; Van Krieken, JH; Verspaget, HW, 1999) |
| "The presence of concomitant primary sclerosing cholangitis (PSC) with inflammatory bowel disease (IBD) represents a distinct disease phenotype that carries a higher risk of colorectal cancer (CRC) than the average IBD patient." | 2.58 | Reviewing the Risk of Colorectal Cancer in Inflammatory Bowel Disease After Liver Transplantation for Primary Sclerosing Cholangitis. ( Kowdley, KV; Lashner, B; Rao, BB, 2018) |
| " In IBD patients, mesalazine dosage ≥ 1." | 2.55 | Chemopreventive effects of 5-aminosalicylic acid on inflammatory bowel disease-associated colorectal cancer and dysplasia: a systematic review with meta-analysis. ( Ma, J; Qiu, X; Wang, K; Zhang, H, 2017) |
| "Mesalamine was associated with a modest reduction in the odds ratio (OR) of CRN (OR = 0." | 2.52 | Mesalamine, but Not Sulfasalazine, Reduces the Risk of Colorectal Neoplasia in Patients with Inflammatory Bowel Disease: An Agent-specific Systematic Review and Meta-analysis. ( Akbari, M; Moss, AC; OʼConnor, A; Packey, CD, 2015) |
| "Ulcerative colitis is a chronic idiopathic inflammatory bowel disease characterized by continuous mucosal inflammation that starts in the rectum and extends proximally." | 2.50 | Ulcerative colitis: epidemiology, diagnosis, and management. ( Cheifetz, AS; Feuerstein, JD, 2014) |
| "The risk of developing colorectal cancer is increased in patients with inflammatory bowel disease." | 2.50 | [Chemoprevention of colorectal cancer in inflammatory bowel disease]. ( Han, SH; Lee, J, 2014) |
| "An increased risk of colorectal cancer (CRC) is present also after LT in IBD patients with primary sclerosing cholangitis (PSC)." | 2.50 | Clinical management of inflammatory bowel disease in the organ recipient. ( Indriolo, A; Ravelli, P, 2014) |
| "Individuals with ulcerative colitis face an increased risk of developing colorectal cancer and would benefit from early chemopreventive intervention." | 2.49 | Differential response of flat and polypoid colitis-associated colorectal neoplasias to chemopreventive agents and heterocyclic amines. ( Chang, WC; Clapper, ML; Cooper, HS; Zenser, TV, 2013) |
| "Ulcerative colitis (UC) and Crohn's disease (CD) represent a chronic inflammatory condition of the bowel that often require lifelong medical therapy for the induction and maintenance of the remission." | 2.49 | Mesalazine for the treatment of inflammatory bowel disease. ( Cottone, M; Criscuoli, V; Modesto, I; Orlando, A, 2013) |
| " Although conclusive evidence is still lacking, epidemiologic studies suggest that long-term use of non-steroidal anti-inflammatory drugs (NSAIDs) has chemopreventive properties against CRC." | 2.49 | Mechanisms of action of non-steroidal anti-inflammatory drugs (NSAIDs) and mesalazine in the chemoprevention of colorectal cancer. ( De Simone, V; Monteleone, G; Pallone, F; Stolfi, C, 2013) |
| " Thus, a general recommendation for long-term use of 5-ASA solely for chemopreventive measures is not warranted." | 2.48 | The role of chemoprevention of colorectal cancer with 5-aminosalicylates in ulcerative colitis. ( Herfarth, H, 2012) |
| "Treatment of patients with ulcerative colitis (UC) has traditionally focused on improving symptoms, with the main objective of inducing and maintaining symptomatic remission." | 2.46 | Importance of mucosal healing in ulcerative colitis. ( Lichtenstein, GR; Rutgeerts, P, 2010) |
| " New dosage regimens are likely to become standard practice in the near future." | 2.46 | Mesalazine in inflammatory bowel disease: a trendy topic once again? ( de Silva, S; Ghosh, S; Iacucci, M, 2010) |
| "Colorectal cancer is a complication of longstanding inflammatory bowel disease." | 2.44 | [Colorectal cancer in inflammatory bowel disease]. ( Henriksen, M; Moum, B, 2007) |
| " Optimal chemoprevention requires long-term use and high dose of aspirin that may increase the risk of gastrointestinal bleeding." | 2.44 | Chemoprevention of colorectal cancer: feasibility in everyday practice? ( Farinati, F; Herszényi, L; Miheller, P; Tulassay, Z, 2008) |
| "ulcerative colitis and Crohn's disease), for both active disease and the control of remission." | 2.44 | Drug insight: aminosalicylates for the treatment of IBD. ( Munck, LK; Nielsen, OH, 2007) |
| "Crohn's disease and ulcerative colitis are two idiopathic inflammatory bowel disorders." | 2.44 | Inflammatory bowel disease: clinical aspects and established and evolving therapies. ( Baumgart, DC; Sandborn, WJ, 2007) |
| "Treatment of ulcerative colitis has changed little in recent years, except for our improved ability to deliver mesalazine to the large bowel via the recent availability of several oral and rectal preparations." | 2.43 | Inflammatory bowel disease. ( Gibson, PR; Iser, J, 2005) |
| "Most of these cases had a history of ulcerative colitis (76 patients)." | 2.43 | 5-Aminosalicylate use and colorectal cancer risk in inflammatory bowel disease: a large epidemiological study. ( Card, T; Leufkens, HG; Logan, RF; van Staa, TP, 2005) |
| "The main risk factors for colorectal cancer are not suitable targets for therapeutic intervention, and primary chemoprevention is an intriguing therapeutic option." | 2.43 | 5-ASA and colorectal cancer chemoprevention in inflammatory bowel disease: can we afford to wait for 'best evidence'? ( Giannini, EG; Kane, SV; Savarino, V; Testa, R, 2005) |
| " However, the minimal dosage to achieve this chemopreventive effect remains unclear." | 2.43 | Prevention of colorectal cancer in inflammatory bowel disease: value of screening and 5-aminosalicylates. ( Esendal, B; Kornbluth, A; Loftus, EV; Mittmann, U; Munkholm, P; Reinacher-Schick, A, 2006) |
| "First-line therapy for ulcerative colitis is 5-aminosalicylic acid, which suffers from poor patient adherence outside the clinical trial setting." | 2.43 | Systematic review: adherence issues in the treatment of ulcerative colitis. ( Kane, SV, 2006) |
| " Similarly, when 5-aminosalicylic acids are used to induce remission, continuing the induction dosage for an extra 4 weeks prolongs remission and reduces the frequency of relapse." | 2.43 | Review article: maintenance therapy in patients with ulcerative colitis. ( Keshav, S; Orchard, T; Probert, CS, 2006) |
| "The colorectal cancer is one of the most serious complication of inflammatory bowel disease." | 2.43 | [Inflammatory bowel disease and colorectal cancer]. ( Hagymási, K; Tulassay, Z, 2006) |
| "Patients with ulcerative colitis (UC) are at greater risk of developing colorectal cancer (CRC) than the general population." | 2.42 | Chemoprevention of colorectal cancer in ulcerative colitis. ( Croog, VJ; Itzkowitz, SH; Ullman, TA, 2003) |
| "Although colorectal cancer (CRC), complicating ulcerative colitis and Crohn's disease, only accounts for 1-2% of all cases of CRC in the general population, it is considered a serious complication of the disease and accounts for approximately 15% of all deaths in inflammatory bowel disease (IBD) patients." | 2.42 | Review article: the incidence and prevalence of colorectal cancer in inflammatory bowel disease. ( Munkholm, P, 2003) |
| "In familial and sporadic colorectal cancer, aspirin, other nonsteroidal anti-inflammatory drugs and cyclo-oxygenase-2 inhibitors have been tested for their ability to reduce polyp and cancer development in clinical studies." | 2.42 | Review article: the chemoprevention of colorectal carcinoma. ( Gasche, C, 2004) |
| "Finally, the risk for development of colorectal cancer increases steadily with disease duration and dysplasia should be screened for by endoscopic surveillance programs." | 2.42 | [Management of ulcerative colitis]. ( Kullak-Ublick, GA; Rammert, Ch, 2003) |
| "The risk of colorectal cancer is increased in ulcerative colitis and Crohn's colitis." | 2.41 | Cancer prevention in inflammatory bowel disease and the chemoprophylactic potential of 5-aminosalicylic acid. ( Bernstein, CN; Eaden, J; Gordon, PH; Munkholm, P; Steinhart, AH, 2002) |
| "Most colorectal cancers (CRC) arise sporadically from precursor lesions: colonic polyps." | 1.62 | 5-Aminosalicylic acid inhibits stem cell function in human adenoma-derived cells: implications for chemoprophylaxis in colorectal tumorigenesis. ( Chambers, AC; Collard, TJ; Creed, TJ; Dixon, SW; Greenhough, A; Legge, DN; Mortensson, EMH; Williams, AC, 2021) |
| "To investigate knowledge and fear of colorectal cancer (CRC) risk in inflammatory bowel disease (IBD) patients." | 1.43 | Patients' knowledge and fear of colorectal cancer risk in inflammatory bowel disease. ( Belle, A; Collet-Fenetrier, B; Lopez, A; Peyrin-Biroulet, L, 2016) |
| "We compared incidence of cancer among IBD patients with that observed in the French Network of population-based Cancer Registries (FRANCIM)." | 1.43 | Cancer in Elderly Onset Inflammatory Bowel Disease: A Population-Based Study. ( Charpentier, C; Cheddani, H; Dauchet, L; Dupas, JL; Fumery, M; Gower-Rousseau, C; Marie Bouvier, A; Pariente, B; Peyrin-Biroulet, L; Savoye, G, 2016) |
| "Studies have demonstrated that ulcerative colitis patients treated with 5-ASA have an overall decrease in the risk of developing colorectal carcinoma." | 1.39 | Protection against peroxynitrite-induced DNA damage by mesalamine: implications for anti-inflammation and anti-cancer activity. ( Dou, X; Graham, PM; Jia, Z; Li, JZ; Li, Y; Misra, HP; Zhu, H, 2013) |
| "Treatment of colorectal cancer with 5-ASA inhibited mTOR signalling in vitro and in vivo." | 1.38 | 5-Aminosalicylic acid inhibits cell cycle progression in a phospholipase D dependent manner in colorectal cancer. ( Baan, B; Bos, CL; Dihal, AA; Hardwick, JC; Heijmans, J; Hoff, E; Hommes, DW; Koelink, PJ; Muncan, V; Peppelenbosch, MP; Richel, DJ; van den Brink, GR; Verspaget, HW; Voorneveld, PW; Wildenberg, ME, 2012) |
| ", an S-phase and G2/M phase arrest, dependent on 5-ASA dosage and concentration, together with an increased mitotic index." | 1.36 | 5-aminosalicylic acid interferes in the cell cycle of colorectal cancer cells and induces cell death modes. ( Corver, WE; Hommes, DW; Koelink, PJ; Lamers, CB; Mieremet-Ooms, MA; Verspaget, HW; Wolanin, K, 2010) |
| "Evaluate factors influencing risk of colorectal cancer development in inflammatory bowel disease patients." | 1.36 | Mesalamine protects against colorectal cancer in inflammatory bowel disease. ( Pai, C; Sharif, O; Silverman, AL; Tang, J, 2010) |
| "The 25-year cumulative rate of colorectal cancer was 23." | 1.35 | Disease activity and cancer risk in inflammatory bowel disease associated with primary sclerosing cholangitis. ( Beaugerie, L; Chazouilleres, O; Cosnes, J; Poupon, R; Seksik, P; Sokol, H; Tiret, E, 2008) |
| " Nonadherence to therapy can be associated with several other factors, including forgetfulness, male sex, complicated dosing regimens, treatment delivery methods (oral vs." | 1.34 | Mild-to-moderate ulcerative colitis: your role in patient compliance and health care costs. ( Boltri, JM; Tindall, WN; Wilhelm, SM, 2007) |
| "In aspirin-treated cultures the mutation rate was 8." | 1.33 | Mesalazine improves replication fidelity in cultured colorectal cells. ( Boland, CR; Gasche, C; Goel, A; Natarajan, L, 2005) |
| "Prevention strategies for colorectal cancer in chronic ulcerative colitis (UC) are currently based on the identification of neoplasia by surveillance colonoscopy, but there is a great interest in the possibility of primary chemoprevention." | 1.33 | Will a 5-ASA a day keep the cancer (and dysplasia) away? ( Lashner, BA; Rubin, DT, 2005) |
| "Interestingly, treatment of ulcerative colitis with mesalazine, which displays few side effects during long-term treatment, is associated with a reduced incidence of colorectal cancer, but its molecular mechanism is not known." | 1.33 | Protein phosphatase 2A is required for mesalazine-dependent inhibition of Wnt/beta-catenin pathway activity. ( Bos, CL; Diks, SH; Hardwick, JC; Peppelenbosch, MP; Richel, DJ; Walburg, KV, 2006) |
| "There is an increased risk of colorectal cancer in patients with inflammatory bowel disease (IBD)." | 1.33 | Distal adenomatous polyps are rare in patients with inflammatory bowel disease. ( Dixon, A; Hart, A; Robinson, R; Wurm, P, 2006) |
| "The risk of colorectal cancer (CRC) in ulcerative colitis (UC) increases with extent and duration of disease." | 1.31 | Colorectal cancer prevention in ulcerative colitis: a case-control study. ( Abrams, K; Eaden, J; Ekbom, A; Jackson, E; Mayberry, J, 2000) |
| "Six patients developed colorectal cancer within the observation period." | 1.28 | Colorectal cancer risk and mortality in patients with ulcerative colitis. ( Binder, V; Davidsen, M; Langholz, E; Munkholm, P, 1992) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (3.05) | 18.2507 |
| 2000's | 55 (41.98) | 29.6817 |
| 2010's | 59 (45.04) | 24.3611 |
| 2020's | 13 (9.92) | 2.80 |
| Authors | Studies |
|---|---|
| Bersuder, E | 1 |
| Terciolo, C | 1 |
| Lechevrel, M | 1 |
| Martin, E | 1 |
| Quesnelle, C | 1 |
| Freund, JN | 1 |
| Reimund, JM | 2 |
| Gross, I | 1 |
| Słoka, J | 1 |
| Madej, M | 1 |
| Strzalka-Mrozik, B | 1 |
| Gros, B | 1 |
| Kaplan, GG | 1 |
| Liang, J | 1 |
| Li, H | 1 |
| Chen, J | 2 |
| He, L | 1 |
| Du, X | 1 |
| Zhou, L | 1 |
| Xiong, Q | 1 |
| Lai, X | 1 |
| Yang, Y | 1 |
| Huang, S | 1 |
| Hou, S | 1 |
| Xu, L | 1 |
| Zhang, Y | 1 |
| Xue, X | 1 |
| Liu, J | 1 |
| Li, ZS | 1 |
| Yang, GY | 1 |
| Song, Y | 1 |
| Pan, Y | 1 |
| Ma, Y | 1 |
| Hu, S | 1 |
| Wen, A | 1 |
| Jia, Y | 1 |
| Rodriguez, LM | 1 |
| Tull, MB | 1 |
| Benante, K | 1 |
| Khan, SA | 1 |
| Cao, Y | 1 |
| Jovanovic, B | 1 |
| Richmond, E | 1 |
| Umar, A | 1 |
| Bergan, R | 1 |
| Wu, K | 1 |
| Fukunaga, S | 1 |
| Kusaba, Y | 1 |
| Tsuruta, O | 1 |
| Casanova, MJ | 1 |
| Chaparro, M | 1 |
| Gisbert, JP | 1 |
| Mak, JWY | 1 |
| So, J | 1 |
| Tang, W | 1 |
| Yip, TCF | 1 |
| Leung, WK | 1 |
| Li, M | 1 |
| Lo, FH | 1 |
| Ng, KM | 1 |
| Sze, SF | 1 |
| Leung, CM | 1 |
| Tsang, SWC | 1 |
| Shan, EHS | 1 |
| Chan, KH | 1 |
| Lam, BCY | 1 |
| Hui, AJ | 1 |
| Chow, WH | 1 |
| Chan, FKL | 1 |
| Ng, SC | 1 |
| Basaranoğlu, M | 1 |
| Kapsigay, M | 1 |
| Kunduz, E | 1 |
| Zeng, J | 1 |
| Meng, ZM | 1 |
| Huang, XL | 1 |
| Gan, HT | 1 |
| Moreno Moraleda, I | 1 |
| Lázaro Sáez, M | 1 |
| Diéguez Castillo, C | 1 |
| Hernández Martínez, Á | 1 |
| Cerón-Carrasco, JP | 1 |
| Jacquemin, D | 1 |
| Dixon, SW | 1 |
| Collard, TJ | 2 |
| Mortensson, EMH | 1 |
| Legge, DN | 1 |
| Chambers, AC | 1 |
| Greenhough, A | 2 |
| Creed, TJ | 1 |
| Williams, AC | 2 |
| Ishikawa, H | 1 |
| Mutoh, M | 1 |
| Sato, Y | 1 |
| Doyama, H | 1 |
| Tajika, M | 1 |
| Tanaka, S | 1 |
| Horimatsu, T | 1 |
| Takeuchi, Y | 1 |
| Kashida, H | 1 |
| Tashiro, J | 1 |
| Ezoe, Y | 1 |
| Nakajima, T | 1 |
| Ikematsu, H | 1 |
| Hori, S | 1 |
| Suzuki, S | 1 |
| Otani, T | 1 |
| Takayama, T | 1 |
| Ohda, Y | 1 |
| Mure, K | 1 |
| Wakabayashi, K | 1 |
| Sakai, T | 1 |
| Filipec Kanizaj, T | 1 |
| Mijic, M | 1 |
| Rao, BB | 1 |
| Lashner, B | 1 |
| Kowdley, KV | 1 |
| Bajpai, M | 1 |
| Seril, DN | 1 |
| Van Gurp, J | 1 |
| Geng, X | 1 |
| Alvarez, J | 1 |
| Minacapelli, CD | 1 |
| Gorin, S | 1 |
| Das, KK | 1 |
| Poplin, E | 1 |
| Cheng, J | 1 |
| Amenta, PS | 1 |
| Das, KM | 1 |
| Rubin, DT | 5 |
| Ananthakrishnan, AN | 1 |
| Siegel, CA | 1 |
| Sauer, BG | 1 |
| Long, MD | 1 |
| Chang, WC | 2 |
| Zenser, TV | 1 |
| Cooper, HS | 2 |
| Clapper, ML | 2 |
| Graham, PM | 1 |
| Li, JZ | 1 |
| Dou, X | 1 |
| Zhu, H | 1 |
| Misra, HP | 1 |
| Jia, Z | 1 |
| Li, Y | 1 |
| Sebastian, S | 1 |
| Hernández, V | 1 |
| Myrelid, P | 1 |
| Kariv, R | 1 |
| Tsianos, E | 1 |
| Toruner, M | 1 |
| Marti-Gallostra, M | 1 |
| Spinelli, A | 1 |
| van der Meulen-de Jong, AE | 1 |
| Yuksel, ES | 1 |
| Gasche, C | 8 |
| Ardizzone, S | 2 |
| Danese, S | 2 |
| Bessissow, T | 1 |
| Bisschops, R | 1 |
| Ferrante, M | 1 |
| Baert, F | 1 |
| Van Assche, G | 1 |
| Rutgeerts, P | 2 |
| Vermeire, S | 1 |
| Criscuoli, V | 1 |
| Modesto, I | 1 |
| Orlando, A | 1 |
| Cottone, M | 1 |
| Nieminen, U | 1 |
| Jussila, A | 1 |
| Nordling, S | 1 |
| Mustonen, H | 1 |
| Färkkilä, MA | 1 |
| Waljee, AK | 2 |
| Stidham, RW | 1 |
| Higgins, PD | 2 |
| Vijan, S | 1 |
| Saini, SD | 1 |
| Stolfi, C | 3 |
| De Simone, V | 1 |
| Pallone, F | 5 |
| Monteleone, G | 5 |
| Lopez, A | 2 |
| Peyrin-Biroulet, L | 5 |
| Margagnoni, G | 1 |
| Pagnini, C | 1 |
| Menasci, F | 1 |
| Festa, S | 1 |
| Delle Fave, G | 1 |
| Galatola, M | 1 |
| Miele, E | 1 |
| Strisciuglio, C | 1 |
| Paparo, L | 1 |
| Rega, D | 1 |
| Delrio, P | 1 |
| Duraturo, F | 1 |
| Martinelli, M | 1 |
| Rossi, GB | 1 |
| Staiano, A | 1 |
| Izzo, P | 1 |
| De Rosa, M | 1 |
| Han, SH | 1 |
| Lee, J | 1 |
| Indriolo, A | 1 |
| Ravelli, P | 1 |
| Zhao, LN | 1 |
| Li, JY | 1 |
| Yu, T | 1 |
| Chen, GC | 1 |
| Yuan, YH | 1 |
| Chen, QK | 1 |
| Chapman, CG | 1 |
| Feuerstein, JD | 1 |
| Cheifetz, AS | 1 |
| Taleban, S | 1 |
| Colombel, JF | 3 |
| Mohler, MJ | 1 |
| Fain, MJ | 1 |
| Urban, BC | 1 |
| Eagle, CJ | 1 |
| Southern, SL | 1 |
| Hamdollah-Zadeh, M | 1 |
| Ghosh, A | 1 |
| Poulsom, R | 1 |
| Paraskeva, C | 1 |
| Silver, A | 1 |
| OʼConnor, A | 1 |
| Packey, CD | 1 |
| Akbari, M | 1 |
| Moss, AC | 1 |
| Do, EJ | 1 |
| Hwang, SW | 1 |
| Kim, SY | 1 |
| Ryu, YM | 1 |
| Cho, EA | 1 |
| Chung, EJ | 1 |
| Park, S | 1 |
| Lee, HJ | 1 |
| Byeon, JS | 1 |
| Ye, BD | 1 |
| Yang, DH | 1 |
| Park, SH | 1 |
| Yang, SK | 1 |
| Kim, JH | 1 |
| Myung, SJ | 1 |
| Saber, MM | 1 |
| Galal, MA | 1 |
| Ain-Shoka, AA | 1 |
| Shouman, SA | 1 |
| Collet-Fenetrier, B | 1 |
| Belle, A | 1 |
| Cheddani, H | 1 |
| Dauchet, L | 1 |
| Fumery, M | 1 |
| Charpentier, C | 1 |
| Marie Bouvier, A | 1 |
| Dupas, JL | 1 |
| Pariente, B | 1 |
| Savoye, G | 1 |
| Gower-Rousseau, C | 1 |
| Qiu, X | 1 |
| Ma, J | 1 |
| Wang, K | 1 |
| Zhang, H | 1 |
| Carrat, F | 1 |
| Seksik, P | 3 |
| Beaugerie, L | 2 |
| Kim, SL | 1 |
| Kim, SH | 1 |
| Park, YR | 1 |
| Liu, YC | 1 |
| Kim, EM | 1 |
| Jeong, HJ | 1 |
| Kim, YN | 1 |
| Seo, SY | 1 |
| Kim, IH | 1 |
| Lee, SO | 1 |
| Lee, ST | 1 |
| Kim, SW | 1 |
| Moussata, D | 1 |
| Allez, M | 1 |
| Cazals-Hatem, D | 1 |
| Treton, X | 1 |
| Laharie, D | 1 |
| Bertheau, P | 1 |
| Bourreille, A | 1 |
| Lavergne-Slove, A | 1 |
| Brixi, H | 1 |
| Branche, J | 1 |
| Gornet, JM | 1 |
| Stefanescu, C | 1 |
| Moreau, J | 1 |
| Marteau, P | 1 |
| Pelletier, AL | 1 |
| Carbonnel, F | 1 |
| Simon, M | 1 |
| Fléjou, JF | 1 |
| Charlois, AL | 1 |
| Roblin, X | 1 |
| Nancey, S | 1 |
| Bouhnik, Y | 1 |
| Berger, F | 1 |
| Flourié, B | 1 |
| Bonovas, S | 1 |
| Fiorino, G | 1 |
| Lytras, T | 1 |
| Nikolopoulos, G | 1 |
| Sokol, H | 1 |
| Cosnes, J | 1 |
| Chazouilleres, O | 1 |
| Tiret, E | 1 |
| Poupon, R | 1 |
| Pellegrini, R | 1 |
| Franze, E | 1 |
| Porro, GB | 1 |
| Ullman, T | 1 |
| Croog, V | 1 |
| Harpaz, N | 2 |
| Hossain, S | 1 |
| Kornbluth, A | 2 |
| Bodian, C | 1 |
| Itzkowitz, S | 2 |
| Herszényi, L | 1 |
| Farinati, F | 1 |
| Miheller, P | 1 |
| Tulassay, Z | 2 |
| Bazuro, GE | 1 |
| Torino, F | 1 |
| Gasparini, G | 1 |
| Capurso, L | 1 |
| Butterworth, JR | 1 |
| Rubenstein, JH | 1 |
| Jeter, JM | 1 |
| Velayos, FS | 4 |
| Ladabaum, U | 1 |
| Huang, XF | 1 |
| Koelink, PJ | 4 |
| Hawinkels, LJ | 1 |
| Wiercinska, E | 1 |
| Sier, CF | 1 |
| ten Dijke, P | 1 |
| Lamers, CB | 3 |
| Hommes, DW | 3 |
| Verspaget, HW | 5 |
| Lichtenstein, GR | 2 |
| Tang, J | 1 |
| Sharif, O | 1 |
| Pai, C | 1 |
| Silverman, AL | 1 |
| Mieremet-Ooms, MA | 1 |
| Corver, WE | 1 |
| Wolanin, K | 1 |
| Parenti, S | 1 |
| Ferrarini, F | 1 |
| Zini, R | 1 |
| Montanari, M | 1 |
| Losi, L | 1 |
| Canovi, B | 1 |
| Ferrari, S | 1 |
| Grande, A | 1 |
| Lyakhovich, A | 1 |
| Low, A | 1 |
| Love, M | 1 |
| Walt, R | 1 |
| Kane, K | 1 |
| Eksteen, B | 1 |
| Goh, J | 1 |
| Iacucci, M | 1 |
| de Silva, S | 1 |
| Ghosh, S | 1 |
| Campregher, C | 3 |
| Honeder, C | 2 |
| Chung, H | 1 |
| Carethers, JM | 1 |
| Allen, PB | 1 |
| Kamm, MA | 1 |
| De Cruz, P | 1 |
| Desmond, PV | 1 |
| Bernstein, CN | 3 |
| Nugent, Z | 1 |
| Blanchard, JF | 1 |
| Kisiel, JB | 1 |
| Loftus, EV | 3 |
| Harmsen, WS | 1 |
| Zinsmeister, AR | 2 |
| Sandborn, WJ | 3 |
| Terdiman, JP | 3 |
| van Schaik, FD | 1 |
| van Oijen, MG | 1 |
| Smeets, HM | 1 |
| van der Heijden, GJ | 1 |
| Siersema, PD | 1 |
| Oldenburg, B | 1 |
| Riyaz, S | 1 |
| Hamlin, J | 1 |
| Everett, S | 1 |
| Di Sabatino, A | 1 |
| Biancheri, P | 1 |
| Rovedatti, L | 1 |
| Macdonald, TT | 1 |
| Corazza, GR | 1 |
| Baan, B | 1 |
| Dihal, AA | 1 |
| Hoff, E | 1 |
| Bos, CL | 2 |
| Voorneveld, PW | 1 |
| Wildenberg, ME | 1 |
| Muncan, V | 1 |
| Heijmans, J | 1 |
| Richel, DJ | 2 |
| Hardwick, JC | 2 |
| Peppelenbosch, MP | 2 |
| van den Brink, GR | 1 |
| Munding, J | 1 |
| Ziebarth, W | 1 |
| Pox, CP | 1 |
| Ladigan, S | 1 |
| Reiser, M | 1 |
| Hüppe, D | 1 |
| Brand, L | 1 |
| Schmiegel, W | 1 |
| Tannapfel, A | 1 |
| Reinacher-Schick, AC | 1 |
| Klotz, U | 1 |
| Zens, B | 1 |
| Scharl, T | 1 |
| Miyoshi, J | 1 |
| Yajima, T | 2 |
| Shimamura, K | 1 |
| Matsuoka, K | 1 |
| Okamoto, S | 1 |
| Higuchi, H | 1 |
| Funakoshi, S | 1 |
| Takaishi, H | 1 |
| Hibi, T | 2 |
| Nguyen, GC | 1 |
| Gulamhusein, A | 1 |
| Actis, GC | 1 |
| Tarallo, S | 1 |
| Rosina, F | 1 |
| Herfarth, H | 2 |
| Eaden, J | 2 |
| Steinhart, AH | 1 |
| Munkholm, P | 5 |
| Gordon, PH | 1 |
| Rammert, Ch | 1 |
| Kullak-Ublick, GA | 1 |
| Croog, VJ | 1 |
| Ullman, TA | 3 |
| Itzkowitz, SH | 2 |
| Allgayer, H | 2 |
| Rutter, M | 1 |
| Saunders, B | 1 |
| Wilkinson, K | 1 |
| Rumbles, S | 1 |
| Schofield, G | 1 |
| Kamm, M | 1 |
| Williams, C | 1 |
| Price, A | 1 |
| Talbot, I | 1 |
| Forbes, A | 1 |
| Desreumaux, P | 1 |
| Romano, O | 1 |
| Lim, WC | 1 |
| Hanauer, SB | 1 |
| Vetter, C | 1 |
| Gibson, PR | 1 |
| Iser, J | 1 |
| Goel, A | 1 |
| Natarajan, L | 1 |
| Boland, CR | 1 |
| Walsh, JM | 1 |
| Lashner, BA | 1 |
| van Staa, TP | 1 |
| Card, T | 1 |
| Logan, RF | 1 |
| Leufkens, HG | 1 |
| Giannini, EG | 1 |
| Kane, SV | 2 |
| Testa, R | 1 |
| Savarino, V | 1 |
| Franchi, L | 2 |
| Fina, D | 2 |
| Caruso, R | 2 |
| Vavassori, P | 1 |
| Monteleone, I | 1 |
| Calabrese, E | 1 |
| Naccari, GC | 2 |
| Bellinvia, S | 2 |
| Testi, R | 2 |
| Ioffe, AIu | 1 |
| Dixon, A | 1 |
| Wurm, P | 1 |
| Hart, A | 1 |
| Robinson, R | 1 |
| Reinacher-Schick, A | 1 |
| Mittmann, U | 1 |
| Esendal, B | 1 |
| Bergman, R | 1 |
| Parkes, M | 1 |
| Kruis, W | 1 |
| Diks, SH | 1 |
| Walburg, KV | 1 |
| Thomsen, OO | 1 |
| Peluso, I | 1 |
| Orchard, T | 1 |
| Probert, CS | 1 |
| Keshav, S | 1 |
| Hagymási, K | 1 |
| Steinbuch, M | 1 |
| Blumentals, WA | 1 |
| Jess, T | 1 |
| Winther, KV | 1 |
| Tremaine, WJ | 1 |
| Scott Harmsen, W | 1 |
| Langholz, E | 2 |
| Binder, V | 2 |
| Luciani, MG | 1 |
| Fortune, JM | 1 |
| Kunkel, TA | 1 |
| Nielsen, OH | 1 |
| Munck, LK | 1 |
| Baumgart, DC | 1 |
| Levine, JS | 1 |
| Burakoff, R | 1 |
| Lakatos, L | 1 |
| Lakatos, PL | 1 |
| Tindall, WN | 1 |
| Boltri, JM | 1 |
| Wilhelm, SM | 1 |
| Cruz-Correa, MR | 1 |
| Jass, JR | 1 |
| Montgomery, EA | 1 |
| Riddell, RH | 1 |
| Rutter, MD | 1 |
| Henriksen, M | 1 |
| Moum, B | 1 |
| Gary, MA | 1 |
| Coudry, RA | 1 |
| Litwin, S | 1 |
| Devarajan, K | 1 |
| Lubet, RA | 1 |
| Bus, PJ | 1 |
| Nagtegaal, ID | 1 |
| Geldof, H | 1 |
| Van Krieken, JH | 1 |
| Griffioen, G | 1 |
| Abrams, K | 1 |
| Ekbom, A | 1 |
| Jackson, E | 1 |
| Mayberry, J | 1 |
| Brown, WA | 1 |
| Farmer, KC | 1 |
| Skinner, SA | 1 |
| Malcontenti-Wilson, C | 1 |
| Misajon, A | 1 |
| O'Brien, PE | 1 |
| Schölmerich, J | 1 |
| Davidsen, M | 1 |
| Grisham, MB | 1 |
| Ware, K | 1 |
| Gilleland, HE | 1 |
| Gilleland, LB | 1 |
| Abell, CL | 1 |
| Yamada, T | 1 |
| Sachar, DB | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Clinical Study to Evaluate the Possible Efficacy and Safety of Roflumilast in Patients With Ulcerative Colitis.[NCT05684484] | Phase 4 | 52 participants (Anticipated) | Interventional | 2023-02-01 | Not yet recruiting | ||
| An Evaluation of Clinical Study Experiences of Patients With Ulcerative Colitis[NCT05737836] | 500 participants (Anticipated) | Observational | 2024-03-31 | Not yet recruiting | |||
| "Azione Chemiopreventiva Della Mesalazina Sul Cancro Del Colon-retto: Studio Pilota Per la Valutazione Degli Effetti Molecolari in Vivo Sulla Via di Segnalazione Proliferativa Della β-catenina (Official Title in Italian Language)"[NCT02077777] | Phase 2 | 21 participants (Actual) | Interventional | 2012-10-31 | Completed | ||
| Manitoba Inflammatory Bowel Disease Cohort Study[NCT03262649] | 388 participants (Actual) | Observational | 2002-03-01 | Completed | |||
| A Pilot Study to Evaluate the Applicability of the Crohn's Disease Endoscopy Index of Severity to Data Obtained by the Colonic Capsule Endoscopy in Ileocolonic Crohn's Disease[NCT01183845] | Phase 4 | 24 participants (Actual) | Interventional | 2009-04-30 | Completed | ||
| Association of Golimumab Trough Levels With Endoscopic and Histologic Healing in Patients With Ulcerative Colitis[NCT03773445] | 52 participants (Actual) | Observational | 2019-03-01 | Completed | |||
| Hypnotherapy for Prevention of Relapse in Ulcerative Colitis: a Randomised, Single-blind, Controlled Clinical Trial[NCT00553163] | 26 participants (Actual) | Interventional | 2007-10-31 | Terminated (stopped due to Unable to recruit sufficient numbers of patinets in the time available) | |||
| An Observational Study of the Immunopathogenesis of and Response to Step-Up Inflammatory Bowel Disease Therapy for Hermansky-Pudlak Syndrome-Associated Colitis[NCT00514982] | Phase 2 | 0 participants (Actual) | Interventional | 2007-08-07 | Withdrawn | ||
| A Randomized Open-label Two-arm Pilot Study to Assess the Safety and Efficacy of Trichuris Suis Ova for the Treatment of Moderate to Severe Chronic Plaque Psoriasis. Protocol: Psoriasis IIT[NCT01836939] | Phase 1 | 8 participants (Actual) | Interventional | 2013-03-31 | Completed | ||
| An Open-label Pilot Study to Assess the Safety and Efficacy of Trichuris Suis Ova for the Treatment of Moderate to Severe Chronic Plaque Psoriasis[NCT01948271] | Phase 1 | 3 participants (Actual) | Interventional | 2013-07-31 | Terminated (stopped due to lack of efficacy) | ||
| Use of Autologous Adult Adipose-Derived Stem/Stromal Cells in Inflammatory Bowel Disease[NCT02952131] | Phase 1/Phase 2 | 100 participants (Anticipated) | Interventional | 2016-11-30 | Enrolling by invitation | ||
| NIH SUBSTUDY:Randomized, Double-blind, Placebo-controlled, Parallel-group Proof-of-concept Study to Assess the Efficacy, Safety and Tolerability of Two Single Infusions of AIN457 in Patients With Moderate to Severe Active Crohn's Disease[NCT00936585] | 2 participants (Actual) | Interventional | 2009-07-31 | Terminated (stopped due to Study halted by the sponsor) | |||
| Effect of Aloe Vera in the Inflammation of Patients With Mild Ulcerative Colitis[NCT01783119] | Early Phase 1 | 60 participants (Anticipated) | Interventional | 2012-08-31 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Measure of anxiety, HADS Hospital anxiety and depression scale. HADS questionnaire consists of a 14 question validated questionnaire, developed to measure anxiety and depression in the hospital setting. Each item is answered by the patient on a four point (0-3) response category so the possible scores range from 0 (minimum) to 21 (maximum) for anxiety and 0 (minimum) to 21 (maximum) for depression. Higher scores indicate worse outcome, (NCT00553163)
Timeframe: 13 weeks
| Intervention | score on a scale (Median) |
|---|---|
| UC Patients Given Gut-focussed Hpynotherapy | 7 |
| UC Patients Given Control Educational Sessions | 10 |
Measure of depression. Each item is answered by the patient on a four point (0-3) response category so the possible scores range from 0 to 21 for anxiety and 0 to 21 for depression. Each item is answered by the patient on a four point (0-3) response category so the possible scores range from 0 (minimum) to 21 (maximum) for anxiety and (minimum) to 21 (maximum) for depression. Higher scores worse outcome. (NCT00553163)
Timeframe: 13 weeks
| Intervention | units on a scale (Median) |
|---|---|
| UC Patients Given Gut-focussed Hypnotherapy | 1.5 |
| UC Patients Given Control Educational Sessions | 4 |
IBDQ (standard measure of IBD patients' Quality of life (QoL) (Irvine et al 1982 approx). The IBDQ is a validated and reliable tool to measure of health-related quality of life in adult patients with IBD. The questionnaire consists of 32 questions scored in four domains: bowel symptoms, emotional health, systemic systems and social function. Scores range from 1 (poorest QoL) to 7 (best QoL). Higher scores indicate better QoL. Lowest score 7, highest score 224. (NCT00553163)
Timeframe: 13 weeks
| Intervention | units on a scale (Median) |
|---|---|
| UC Patients Given Gut-focussed Hypnotherapy | 195 |
| UC Patients Given Control Educational Sessions | 192 |
Measure of recent psychological stress. THE PSQ R consists of a 30 question questionnaires: recent, in which the statements used apply to the last month in which used statements apply to the last two years (Appendix 1.3). The score for both recent and general stress levels were stated as the PSQ index ranging from 0 (non-stressed) to 0.99 (highly stressed). Higher scores indicate worse outcome. (NCT00553163)
Timeframe: 13 weeks
| Intervention | units on a scale (Median) |
|---|---|
| UC Patients Given Gut-focussed Hypnotherapy | 0.3 |
| UC Patients Given Control Educational Sessions | 0.4 |
The number of patients suffering a relapse was compared between the two treatment groups, and was the primary outcome parameter of this study. (NCT00553163)
Timeframe: 1 year
| Intervention | Participants (Count of Participants) |
|---|---|
| UC Patients Given Gut-focussed Hypnotherapy | 8 |
| UC Patients Given Control Educational Sessions | 7 |
57 reviews available for mesalamine and Colorectal Cancer
| Article | Year |
|---|---|
Molecular Mechanisms of the Antitumor Effects of Mesalazine and Its Preventive Potential in Colorectal Cancer.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Colorectal Neoplasms; Crohn Disease; H | 2023 |
Ulcerative Colitis in Adults: A Review.
Topics: Adult; Antibodies, Monoclonal; Colitis, Ulcerative; Colorectal Neoplasms; Female; Humans; Inflammati | 2023 |
Effects of 5-aminosalicylates or thiopurines on the progression of low-grade dysplasia in patients with inflammatory bowel disease: a systematic review and meta-analysis.
Topics: Colitis; Colorectal Neoplasms; Humans; Inflammatory Bowel Diseases; Mesalamine; Risk Factors | 2021 |
Inflammatory bowel disease in liver transplanted patients.
Topics: Algorithms; Anastomosis, Surgical; Cholangitis, Sclerosing; Colonoscopy; Colorectal Neoplasms; Femal | 2017 |
Reviewing the Risk of Colorectal Cancer in Inflammatory Bowel Disease After Liver Transplantation for Primary Sclerosing Cholangitis.
Topics: Cholangitis, Sclerosing; Colonoscopy; Colorectal Neoplasms; Humans; Inflammatory Bowel Diseases; Liv | 2018 |
Differential response of flat and polypoid colitis-associated colorectal neoplasias to chemopreventive agents and heterocyclic amines.
Topics: Amines; Animals; Anti-Inflammatory Agents, Non-Steroidal; Apoptosis; Carcinogens; Cell Proliferation | 2013 |
Colorectal cancer in inflammatory bowel disease: results of the 3rd ECCO pathogenesis scientific workshop (I).
Topics: Age of Onset; Anticarcinogenic Agents; Cholangitis, Sclerosing; Colitis, Ulcerative; Colorectal Neop | 2014 |
Mesalazine for the treatment of inflammatory bowel disease.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Colorectal Neoplasms; Crohn Disease; H | 2013 |
Mechanisms of action of non-steroidal anti-inflammatory drugs (NSAIDs) and mesalazine in the chemoprevention of colorectal cancer.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Chemoprevention; Colorectal Neoplasms; Humans; Mes | 2013 |
5-Aminosalicylic acid and chemoprevention: does it work?
Topics: Chemoprevention; Colorectal Neoplasms; Evidence-Based Medicine; Humans; Inflammatory Bowel Diseases; | 2013 |
Critical review of the evidence on 5-aminosalicilate for chemoprevention of colorectal cancer in ulcerative colitis: a methodological question.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Chemoprevention; Colitis, Ulcerative; Colorectal Neoplasms; | 2014 |
[Chemoprevention of colorectal cancer in inflammatory bowel disease].
Topics: Anti-Inflammatory Agents; Chemoprevention; Colorectal Neoplasms; Folic Acid; Immunosuppressive Agent | 2014 |
Clinical management of inflammatory bowel disease in the organ recipient.
Topics: Azathioprine; Cholangitis, Sclerosing; Colectomy; Colorectal Neoplasms; End Stage Liver Disease; Gra | 2014 |
5-Aminosalicylates reduce the risk of colorectal neoplasia in patients with ulcerative colitis: an updated meta-analysis.
Topics: Colitis, Ulcerative; Colorectal Neoplasms; Humans; Mesalamine; Risk | 2014 |
The potential for medical therapy to reduce the risk of colorectal cancer and optimize surveillance in inflammatory bowel disease.
Topics: Adenocarcinoma; Anti-Inflammatory Agents, Non-Steroidal; Azathioprine; Cholagogues and Choleretics; | 2014 |
Ulcerative colitis: epidemiology, diagnosis, and management.
Topics: Adrenal Cortex Hormones; Anti-Inflammatory Agents, Non-Steroidal; Colectomy; Colitis, Ulcerative; Co | 2014 |
Ulcerative colitis: epidemiology, diagnosis, and management.
Topics: Adrenal Cortex Hormones; Anti-Inflammatory Agents, Non-Steroidal; Colectomy; Colitis, Ulcerative; Co | 2014 |
Ulcerative colitis: epidemiology, diagnosis, and management.
Topics: Adrenal Cortex Hormones; Anti-Inflammatory Agents, Non-Steroidal; Colectomy; Colitis, Ulcerative; Co | 2014 |
Ulcerative colitis: epidemiology, diagnosis, and management.
Topics: Adrenal Cortex Hormones; Anti-Inflammatory Agents, Non-Steroidal; Colectomy; Colitis, Ulcerative; Co | 2014 |
Inflammatory bowel disease and the elderly: a review.
Topics: Aged; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Colorectal Neoplasms; Diagnosi | 2015 |
Mesalamine, but Not Sulfasalazine, Reduces the Risk of Colorectal Neoplasia in Patients with Inflammatory Bowel Disease: An Agent-specific Systematic Review and Meta-analysis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Colorectal Neoplasms; Humans; Inflammatory Bowel Diseases; | 2015 |
Chemopreventive effects of 5-aminosalicylic acid on inflammatory bowel disease-associated colorectal cancer and dysplasia: a systematic review with meta-analysis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Chemoprevention; Cohort Studies; Colorectal Neoplasms; Huma | 2017 |
Systematic review with meta-analysis: use of 5-aminosalicylates and risk of colorectal neoplasia in patients with inflammatory bowel disease.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Colorectal Neoplasms; Crohn Disease; H | 2017 |
Molecular basis of the potential of mesalazine to prevent colorectal cancer.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Cell Proliferation; Cell Survival; C | 2008 |
Chemoprevention of colorectal cancer: feasibility in everyday practice?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Aspirin; Chemoprevention; Clinical T | 2008 |
Chemoprevention in gastrointestinal adenocarcinoma: for few but not for all?
Topics: Adenocarcinoma; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Colorectal Neoplasms; ErbB Recepto | 2008 |
Importance of mucosal healing in ulcerative colitis.
Topics: Adrenal Cortex Hormones; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Antibodi | 2010 |
[For treatment decision the age to be taken into account. In Crohn's disease and ulcerative colitis attention to be paid to the age at manifestation].
Topics: Adolescent; Adult; Age Factors; Aged; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroi | 2009 |
Systematic review: molecular chemoprevention of colorectal malignancy by mesalazine.
Topics: Cell Line, Tumor; Chemoprevention; Colorectal Neoplasms; Humans; Inflammatory Bowel Diseases; Intest | 2010 |
Mesalazine in inflammatory bowel disease: a trendy topic once again?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Colorectal Neoplasms; Crohn Disease; H | 2010 |
Dysplastic lesions in ulcerative colitis: changing paradigms.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Colectomy; Colitis, Ulcerative; Colonic Polyps; Colonoscopy | 2010 |
Recent advances in understanding ulcerative colitis.
Topics: Biopsy, Needle; Colectomy; Colitis, Ulcerative; Colorectal Neoplasms; Combined Modality Therapy; Dis | 2012 |
The pharmacological profile and clinical use of mesalazine (5-aminosalicylic acid).
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Colorectal Neoplasms; Crohn Disease; Drug Delivery | 2012 |
Colorectal cancer chemoprevention by mesalazine and its derivatives.
Topics: Cell Survival; Colorectal Neoplasms; DNA Replication; ErbB Receptors; Humans; Inflammatory Bowel Dis | 2012 |
5-aminosalicylic acid is not protective against colorectal cancer in inflammatory bowel disease: a meta-analysis of non-referral populations.
Topics: Colorectal Neoplasms; Humans; Inflammatory Bowel Diseases; Mesalamine | 2012 |
Cutting edge: chemoprevention of colorectal neoplasia in inflammatory bowel disease.
Topics: Animals; Anti-Inflammatory Agents; Cell Transformation, Neoplastic; Chemoprevention; Colonoscopy; Co | 2013 |
The role of chemoprevention of colorectal cancer with 5-aminosalicylates in ulcerative colitis.
Topics: Adenocarcinoma; Adenoma; Animals; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Colo | 2012 |
Cancer prevention in inflammatory bowel disease and the chemoprophylactic potential of 5-aminosalicylic acid.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Colorectal Neoplasms; Humans; Inflammatory Bowel Diseases; | 2002 |
[Management of ulcerative colitis].
Topics: Administration, Oral; Adrenal Cortex Hormones; Aminosalicylic Acids; Anemia; Anti-Inflammatory Agent | 2003 |
Chemoprevention of colorectal cancer in ulcerative colitis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Calcium, Dietary; Chemoprevention; Cholagogues and Choleret | 2003 |
Review article: the incidence and prevalence of colorectal cancer in inflammatory bowel disease.
Topics: Adenocarcinoma; Age of Onset; Anti-Inflammatory Agents, Non-Steroidal; Colorectal Neoplasms; Humans; | 2003 |
Review article: mechanisms of action of mesalazine in preventing colorectal carcinoma in inflammatory bowel disease.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cell Division; Colorectal Neoplasms; Cyclooxygenase 1; Cycl | 2003 |
Diagnosis and management of dysplasia in patients with inflammatory bowel diseases.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Colonoscopy; Colorectal Neoplasms; Humans; Inflammatory Bow | 2004 |
Review article: the chemoprevention of colorectal carcinoma.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Aspirin; Chemoprevention; Chromosoma | 2004 |
Controversies with aminosalicylates in inflammatory bowel disease.
Topics: Aminosalicylic Acids; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Chemopreventi | 2004 |
Inflammatory bowel disease.
Topics: Adrenal Cortex Hormones; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Colonoscopy; | 2005 |
Effect of 5-aminosalicylate use on colorectal cancer and dysplasia risk: a systematic review and metaanalysis of observational studies.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Clinical Trials as Topic; Colitis, Ulcerative; Color | 2005 |
Effect of 5-aminosalicylate use on colorectal cancer and dysplasia risk: a systematic review and metaanalysis of observational studies.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Clinical Trials as Topic; Colitis, Ulcerative; Color | 2005 |
Effect of 5-aminosalicylate use on colorectal cancer and dysplasia risk: a systematic review and metaanalysis of observational studies.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Clinical Trials as Topic; Colitis, Ulcerative; Color | 2005 |
Effect of 5-aminosalicylate use on colorectal cancer and dysplasia risk: a systematic review and metaanalysis of observational studies.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Clinical Trials as Topic; Colitis, Ulcerative; Color | 2005 |
5-Aminosalicylate use and colorectal cancer risk in inflammatory bowel disease: a large epidemiological study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Case-Control St | 2005 |
5-ASA and colorectal cancer chemoprevention in inflammatory bowel disease: can we afford to wait for 'best evidence'?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Chemoprevention; Clinical Trials as Topic; Colorectal Neopl | 2005 |
Prevention of colorectal cancer in inflammatory bowel disease: value of screening and 5-aminosalicylates.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Biopsy; Colonoscopy; Colorectal Neoplasms; Humans; Inflamma | 2006 |
Systematic review: adherence issues in the treatment of ulcerative colitis.
Topics: Administration, Oral; Administration, Rectal; Anti-Inflammatory Agents, Non-Steroidal; Attitude to H | 2006 |
Systematic review: the use of mesalazine in inflammatory bowel disease.
Topics: Acute Disease; Administration, Oral; Administration, Topical; Anti-Inflammatory Agents, Non-Steroida | 2006 |
Systematic review: the use of mesalazine in inflammatory bowel disease.
Topics: Acute Disease; Administration, Oral; Administration, Topical; Anti-Inflammatory Agents, Non-Steroida | 2006 |
Systematic review: the use of mesalazine in inflammatory bowel disease.
Topics: Acute Disease; Administration, Oral; Administration, Topical; Anti-Inflammatory Agents, Non-Steroida | 2006 |
Systematic review: the use of mesalazine in inflammatory bowel disease.
Topics: Acute Disease; Administration, Oral; Administration, Topical; Anti-Inflammatory Agents, Non-Steroida | 2006 |
Review article: maintenance therapy in patients with ulcerative colitis.
Topics: Administration, Oral; Administration, Topical; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulc | 2006 |
[Inflammatory bowel disease and colorectal cancer].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cholangitis, Sclerosing; Colitis, Ulcerative; Colonoscopy; | 2006 |
Drug insight: aminosalicylates for the treatment of IBD.
Topics: Aminosalicylic Acids; Anti-Inflammatory Agents, Non-Steroidal; Chemoprevention; Colitis, Ulcerative; | 2007 |
Inflammatory bowel disease: clinical aspects and established and evolving therapies.
Topics: Algorithms; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Colorectal Neoplasms; Croh | 2007 |
Inflammatory bowel disease: clinical aspects and established and evolving therapies.
Topics: Algorithms; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Colorectal Neoplasms; Croh | 2007 |
Inflammatory bowel disease: clinical aspects and established and evolving therapies.
Topics: Algorithms; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Colorectal Neoplasms; Croh | 2007 |
Inflammatory bowel disease: clinical aspects and established and evolving therapies.
Topics: Algorithms; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Colorectal Neoplasms; Croh | 2007 |
Inflammatory bowel disease: clinical aspects and established and evolving therapies.
Topics: Algorithms; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Colorectal Neoplasms; Croh | 2007 |
Inflammatory bowel disease: clinical aspects and established and evolving therapies.
Topics: Algorithms; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Colorectal Neoplasms; Croh | 2007 |
Inflammatory bowel disease: clinical aspects and established and evolving therapies.
Topics: Algorithms; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Colorectal Neoplasms; Croh | 2007 |
Inflammatory bowel disease: clinical aspects and established and evolving therapies.
Topics: Algorithms; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Colorectal Neoplasms; Croh | 2007 |
Inflammatory bowel disease: clinical aspects and established and evolving therapies.
Topics: Algorithms; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Colorectal Neoplasms; Croh | 2007 |
Inflammatory bowel disease: clinical aspects and established and evolving therapies.
Topics: Algorithms; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Colorectal Neoplasms; Croh | 2007 |
Inflammatory bowel disease: clinical aspects and established and evolving therapies.
Topics: Algorithms; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Colorectal Neoplasms; Croh | 2007 |
Inflammatory bowel disease: clinical aspects and established and evolving therapies.
Topics: Algorithms; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Colorectal Neoplasms; Croh | 2007 |
Inflammatory bowel disease: clinical aspects and established and evolving therapies.
Topics: Algorithms; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Colorectal Neoplasms; Croh | 2007 |
Inflammatory bowel disease: clinical aspects and established and evolving therapies.
Topics: Algorithms; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Colorectal Neoplasms; Croh | 2007 |
Inflammatory bowel disease: clinical aspects and established and evolving therapies.
Topics: Algorithms; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Colorectal Neoplasms; Croh | 2007 |
Inflammatory bowel disease: clinical aspects and established and evolving therapies.
Topics: Algorithms; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Colorectal Neoplasms; Croh | 2007 |
Inflammatory bowel disease: clinical aspects and established and evolving therapies.
Topics: Algorithms; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Colorectal Neoplasms; Croh | 2007 |
Inflammatory bowel disease: clinical aspects and established and evolving therapies.
Topics: Algorithms; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Colorectal Neoplasms; Croh | 2007 |
Inflammatory bowel disease: clinical aspects and established and evolving therapies.
Topics: Algorithms; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Colorectal Neoplasms; Croh | 2007 |
Inflammatory bowel disease: clinical aspects and established and evolving therapies.
Topics: Algorithms; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Colorectal Neoplasms; Croh | 2007 |
Inflammatory bowel disease: clinical aspects and established and evolving therapies.
Topics: Algorithms; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Colorectal Neoplasms; Croh | 2007 |
Inflammatory bowel disease: clinical aspects and established and evolving therapies.
Topics: Algorithms; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Colorectal Neoplasms; Croh | 2007 |
Inflammatory bowel disease: clinical aspects and established and evolving therapies.
Topics: Algorithms; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Colorectal Neoplasms; Croh | 2007 |
Inflammatory bowel disease: clinical aspects and established and evolving therapies.
Topics: Algorithms; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Colorectal Neoplasms; Croh | 2007 |
Inflammatory bowel disease: clinical aspects and established and evolving therapies.
Topics: Algorithms; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Colorectal Neoplasms; Croh | 2007 |
Chemoprophylaxis of colorectal cancer in inflammatory bowel disease: current concepts.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Azathioprine; Cholagogues and Choleretics; Colorectal Neopl | 2007 |
[Medical therapy of inflammatory bowel diseases: ulcerative colitis].
Topics: Administration, Oral; Adrenal Cortex Hormones; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, | 2007 |
Colorectal cancer prevention in inflammatory bowel disease and the role of 5-aminosalicylic acid: a clinical review and update.
Topics: Adenomatous Polyposis Coli; Anti-Inflammatory Agents, Non-Steroidal; Colorectal Neoplasms; Humans; I | 2008 |
[Colorectal cancer in inflammatory bowel disease].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Colonoscopy; Colorectal Neoplasms; Cro | 2007 |
4 trials available for mesalamine and Colorectal Cancer
| Article | Year |
|---|---|
A Phase I Trial of Berberine in Chinese with Ulcerative Colitis.
Topics: Administration, Oral; Adult; Anti-Inflammatory Agents, Non-Steroidal; Berberine; Biopsy; China; Coli | 2020 |
Chemoprevention with low-dose aspirin, mesalazine, or both in patients with familial adenomatous polyposis without previous colectomy (J-FAPP Study IV): a multicentre, double-blind, randomised, two-by-two factorial design trial.
Topics: Adenomatous Polyposis Coli; Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Case-Control St | 2021 |
Are random biopsies still useful for the detection of neoplasia in patients with IBD undergoing surveillance colonoscopy with chromoendoscopy?
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Biopsy; Colitis, Ulcerative; Colonoscopy; Colorectal | 2018 |
Mesalazine-induced apoptosis of colorectal cancer: on the verge of a new chemopreventive era?
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Apoptosis; Biomarkers; Cell Division; Cells, Cultured | 1999 |
70 other studies available for mesalamine and Colorectal Cancer
| Article | Year |
|---|---|
Mesalazine initiates an anti-oncogenic β-catenin / MUCDHL negative feed-back loop in colon cancer cells by cell-specific mechanisms.
Topics: beta Catenin; Cadherin Related Proteins; Cadherins; Colonic Neoplasms; Colorectal Neoplasms; Humans; | 2022 |
Dendrobium officinale polysaccharides alleviate colon tumorigenesis via restoring intestinal barrier function and enhancing anti-tumor immune response.
Topics: Animals; Antineoplastic Agents; Carcinogenesis; CD8-Positive T-Lymphocytes; Colitis; Colon; Colorect | 2019 |
Use of Endocytoscopy for Ulcerative Colitis Surveillance: A Case Study.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Biopsy; Colitis, Ulcerative; Colonic Neoplasms; Colo | 2020 |
Errors in the care of inflammatory bowel disease patients: "Errata" Study.
Topics: Adrenal Cortex Hormones; Adult; Aged; Aged, 80 and over; Ambulatory Care; Colonoscopy; Colorectal Ne | 2020 |
Cancer risk and chemoprevention in Chinese inflammatory bowel disease patients: a population-based cohort study.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; China; Cohort Studies; Colitis, Ulcerative; | 2020 |
Increased neuroendocrine tumours, but small colorectal cancer incidence in patients with inflammatory bowel disease treated by mesalazine.
Topics: Colorectal Neoplasms; Humans; Incidence; Inflammatory Bowel Diseases; Matched-Pair Analysis; Mesalam | 2020 |
Inflammatory bowel disease and inherited colorectal cancer: Is there a genetic link?
Topics: Adenocarcinoma; Adult; Age of Onset; Anti-Inflammatory Agents; Azathioprine; Breast Neoplasms; Colit | 2021 |
Using Theory To Extend the Scope of Azobenzene Drugs in Chemotherapy: Novel Combinations for a Specific Delivery.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Azo Compounds; Colon; Colorectal Neo | 2021 |
5-Aminosalicylic acid inhibits stem cell function in human adenoma-derived cells: implications for chemoprophylaxis in colorectal tumorigenesis.
Topics: Adenoma; Carcinogenesis; Carcinoma; Cell Line, Tumor; Cell Transformation, Neoplastic; Chemopreventi | 2021 |
Effect of Long-Term Mesalamine Therapy on Cancer-Associated Gene Expression in Colonic Mucosa of Patients with Ulcerative Colitis.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Biopsy; Cell Line, Tu | 2019 |
ACG Clinical Guideline: Ulcerative Colitis in Adults.
Topics: Adalimumab; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Biopsy; Budesonide; C | 2019 |
Protection against peroxynitrite-induced DNA damage by mesalamine: implications for anti-inflammation and anti-cancer activity.
Topics: Anti-Inflammatory Agents; Anticarcinogenic Agents; Bacteriophage phi X 174; Colitis, Ulcerative; Col | 2013 |
5-aminosalicylate is not protective from neoplasia in ulcerative colitis.
Topics: Colorectal Neoplasms; Humans; Inflammatory Bowel Diseases; Mesalamine | 2013 |
Inflammation and disease duration have a cumulative effect on the risk of dysplasia and carcinoma in IBD: a case-control observational study based on registry data.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; | 2014 |
Point-counterpoint: Are we overtreating patients with mild ulcerative colitis?
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Colectomy; Colitis, Ulcerative; Colorectal Neoplasms | 2014 |
Synergistic effect of interleukin-10-receptor variants in a case of early-onset ulcerative colitis.
Topics: Adenomatous Polyposis Coli; Age of Onset; Anti-Infective Agents; Azathioprine; beta Catenin; Biomark | 2013 |
BCL-3 expression promotes colorectal tumorigenesis through activation of AKT signalling.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Apoptosis; B-Cell Lymphoma 3 Protein; Cell Prolife | 2016 |
Suppression of colitis-associated carcinogenesis through modulation of IL-6/STAT3 pathway by balsalazide and VSL#3.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Azoxymethane; bcl-2-Assoc | 2016 |
Combination of metformin and 5-aminosalicylic acid cooperates to decrease proliferation and induce apoptosis in colorectal cancer cell lines.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Apoptosis; Caco-2 Cells; Cell Proliferation; Colorectal Neo | 2016 |
Patients' knowledge and fear of colorectal cancer risk in inflammatory bowel disease.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Colectomy; Colitis, Ulcerat | 2016 |
Cancer in Elderly Onset Inflammatory Bowel Disease: A Population-Based Study.
Topics: Adrenal Cortex Hormones; Age of Onset; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroi | 2016 |
The effects of aminosalicylates or thiopurines on the risk of colorectal cancer in inflammatory bowel disease.
Topics: Adult; Aged; Aminosalicylic Acids; Anti-Inflammatory Agents, Non-Steroidal; Case-Control Studies; Co | 2017 |
Combined Parthenolide and Balsalazide Have Enhanced Antitumor Efficacy Through Blockade of NF-κB Activation.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Combined Chemotherapy Protocols; Ap | 2017 |
Disease activity and cancer risk in inflammatory bowel disease associated with primary sclerosing cholangitis.
Topics: Adolescent; Adult; Anti-Inflammatory Agents, Non-Steroidal; Case-Control Studies; Cholangitis, Scler | 2008 |
How long is it advisable to prolong maintenance treatment of patients with ulcerative colitis?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Colorectal Neoplasms; Humans; Mesalami | 2008 |
Progression to colorectal neoplasia in ulcerative colitis: effect of mesalamine.
Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Chemoprevention; Child; Cohort Stu | 2008 |
Chemoprevention of colorectal cancer in inflammatory bowel disease.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Colorectal Neoplasms; Comorbidity; Gene Expression; Humans; | 2009 |
Cost effectiveness of ulcerative colitis surveillance in the setting of 5-aminosalicylates.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Colono | 2009 |
Beta-catenin pathway in ulcerative colitis-associated colorectal cancer and therapeutic implication.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; beta Catenin; Cell Transformation, Neoplastic; Col | 2009 |
5-Aminosalicylic acid inhibits TGF-beta1 signalling in colorectal cancer cells.
Topics: Active Transport, Cell Nucleus; Anti-Inflammatory Agents, Non-Steroidal; Cell Line, Tumor; Colorecta | 2010 |
Mesalamine protects against colorectal cancer in inflammatory bowel disease.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Case-Control Studies; Chi-S | 2010 |
5-aminosalicylic acid interferes in the cell cycle of colorectal cancer cells and induces cell death modes.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Apoptosis; Caco-2 Cells; Cell Division; Colorectal Neoplasm | 2010 |
Mesalazine inhibits the beta-catenin signalling pathway acting through the upregulation of mu-protocadherin gene in colo-rectal cancer cells.
Topics: beta Catenin; Cadherins; Cell Line, Tumor; Colorectal Neoplasms; Gene Expression Regulation, Neoplas | 2010 |
Understanding of chemoprophylaxis and concordance in inflammatory bowel disease.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cholagogues and Choleretics; Colorectal Neoplasms; Humans; | 2010 |
Mesalazine reduces mutations in transforming growth factor beta receptor II and activin type II receptor by improvement of replication fidelity in mononucleotide repeats.
Topics: Activin Receptors, Type II; Anti-Inflammatory Agents, Non-Steroidal; Blotting, Southern; Colorectal | 2010 |
5-aminosalicylate is not chemoprophylactic for colorectal cancer in IBD: a population based study.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Case-Control Studies; Cohort Studies; Colitis, Ulcer | 2011 |
Outcome of sporadic adenomas and adenoma-like dysplasia in patients with ulcerative colitis undergoing polypectomy.
Topics: Adenoma; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Cell T | 2012 |
The prevention of colitis-related cancer by 5-aminosalicylates: an appealing hypothesis that remains unproven.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Colitis; Colorectal Neoplasms; Humans; Mesalamine; Models, | 2011 |
Thiopurines prevent advanced colorectal neoplasia in patients with inflammatory bowel disease.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Azathioprine; Cohort Studies; Colorectal Neoplasms; | 2012 |
Role of 5-aminosalicylate in preventing colorectal cancer.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Colorectal Neoplasms; Female; Humans; Inflammatory Bowel Di | 2011 |
5-Aminosalicylic acid inhibits cell cycle progression in a phospholipase D dependent manner in colorectal cancer.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Biomarkers, Tumor; Blotting, Western; Cell Cycle; Cell Line | 2012 |
The influence of 5-aminosalicylic acid on the progression of colorectal adenomas via the β-catenin signaling pathway.
Topics: Adenoma; beta Catenin; Cadherins; Cell Line, Tumor; Colitis, Ulcerative; Colorectal Neoplasms; Cycli | 2012 |
Improvement of replication fidelity by certain mesalazine derivatives.
Topics: Adaptor Proteins, Signal Transducing; Anticarcinogenic Agents; Ataxia Telangiectasia Mutated Protein | 2012 |
5-aminosalicylic acid mediates expression of cyclooxygenase-2 and 15-hydroxyprostaglandin dehydrogenase to suppress colorectal tumorigenesis.
Topics: Animals; Colorectal Neoplasms; Cyclooxygenase 2; HT29 Cells; Humans; Hydroxyprostaglandin Dehydrogen | 2012 |
[Chemoprevention of colorectal cancer associated with IBD].
Topics: Azathioprine; Colorectal Neoplasms; Crohn Disease; Folic Acid; Humans; Inflammatory Bowel Diseases; | 2012 |
Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis.
Topics: Adolescent; Adult; Case-Control Studies; Child; Colitis, Ulcerative; Colonoscopy; Colorectal Neoplas | 2004 |
Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis.
Topics: Adolescent; Adult; Case-Control Studies; Child; Colitis, Ulcerative; Colonoscopy; Colorectal Neoplas | 2004 |
Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis.
Topics: Adolescent; Adult; Case-Control Studies; Child; Colitis, Ulcerative; Colonoscopy; Colorectal Neoplas | 2004 |
Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis.
Topics: Adolescent; Adult; Case-Control Studies; Child; Colitis, Ulcerative; Colonoscopy; Colorectal Neoplas | 2004 |
[5-aminosalicylates and colorectal cancer: preventive role in chronic inflammatory bowel disease?].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Colorectal Neoplasms; Humans; Inflammatory Bowel Diseases; | 2004 |
[Chronic inflammatory bowel diseases. Recurrence prevention = carcinoma prevention?].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Azathioprine; Cholangitis, Sclerosing; Colitis, Ulcerative; | 2005 |
Mesalazine improves replication fidelity in cultured colorectal cells.
Topics: Aspirin; Base Pair Mismatch; Cell Survival; Colorectal Neoplasms; DNA Repair; DNA Replication; Flow | 2005 |
Will a 5-ASA a day keep the cancer (and dysplasia) away?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Colorectal Neoplasms; Disease Progress | 2005 |
Silencing of SH-PTP2 defines a crucial role in the inactivation of epidermal growth factor receptor by 5-aminosalicylic acid in colon cancer cells.
Topics: Adenocarcinoma; Apoptosis; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Colorectal Neopl | 2006 |
[Primary chemoprevention of colorectal cancer in patients with inflammatory bowel diseases].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Chemoprevention; Colorectal Neoplasms; Humans; Inflammatory | 2005 |
Distal adenomatous polyps are rare in patients with inflammatory bowel disease.
Topics: Adenomatous Polyps; Antimetabolites, Antineoplastic; Azathioprine; Case-Control Studies; Colorectal | 2006 |
Chemoprevention of colorectal neoplasia in ulcerative colitis: the effect of 6-mercaptopurine.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antimetabolites, Antineoplastic; Azathioprine; Colitis, Ulc | 2006 |
Protein phosphatase 2A is required for mesalazine-dependent inhibition of Wnt/beta-catenin pathway activity.
Topics: Anti-Inflammatory Agents, Non-Steroidal; beta Catenin; Cell Line, Tumor; Colitis, Ulcerative; Coloni | 2006 |
[5-aminosalicylic acid and cancer prophylaxis?].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Colorectal Neoplasms; Humans; Mesalami | 2006 |
5-aminosalicylic acid enhances anchorage-independent colorectal cancer cell death.
Topics: Anoikis; Antineoplastic Agents; Blotting, Western; Cell Line, Tumor; Colorectal Neoplasms; Genes, bc | 2006 |
5-Aminosalicylic acid therapy and the risk of colorectal cancer among patients with inflammatory bowel disease.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Case-Control Studies; Colorectal Neoplasms; Female; H | 2007 |
Risk factors for colorectal neoplasia in inflammatory bowel disease: a nested case-control study from Copenhagen county, Denmark and Olmsted county, Minnesota.
Topics: Adult; Case-Control Studies; Colonoscopy; Colorectal Neoplasms; Denmark; Female; Gastrointestinal Ag | 2007 |
5-ASA affects cell cycle progression in colorectal cells by reversibly activating a replication checkpoint.
Topics: Adaptor Proteins, Signal Transducing; Anti-Inflammatory Agents, Non-Steroidal; Apoptosis; Ataxia Tel | 2007 |
5-ASA and colorectal cell-cycle progression.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Caco-2 Cells; Cell Cycle; Cell Death; Colorectal Neoplasms; | 2007 |
Mild-to-moderate ulcerative colitis: your role in patient compliance and health care costs.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Colorectal Neoplasms; Controlled Clini | 2007 |
5-aminosalicylic acid inhibits colitis-associated colorectal dysplasias in the mouse model of azoxymethane/dextran sulfate sodium-induced colitis.
Topics: Animals; Azoxymethane; Colitis; Colorectal Neoplasms; Cyclooxygenase 2; Dextran Sulfate; Disease Mod | 2008 |
Colorectal cancer prevention in ulcerative colitis: a case-control study.
Topics: Adolescent; Adult; Anti-Inflammatory Agents, Non-Steroidal; Case-Control Studies; Colitis, Ulcerativ | 2000 |
5-aminosalicyclic acid and olsalazine inhibit tumor growth in a rodent model of colorectal cancer.
Topics: Aminosalicylic Acids; Animals; Anti-Inflammatory Agents, Non-Steroidal; Apoptosis; Cell Division; Co | 2000 |
[Value of therapy with 5-aminosalicylic acid in chemoprevention of colorectal carcinoma in ulcerative colitis].
Topics: Case-Control Studies; Colitis, Ulcerative; Colorectal Neoplasms; Humans; Mesalamine; Retrospective S | 2000 |
[Mesalazine in ulcerative colitis. Fewer cases of colorectal carcinoma].
Topics: Adolescent; Adult; Age Factors; Anti-Inflammatory Agents, Non-Steroidal; Case-Control Studies; Child | 2002 |
Colorectal cancer risk and mortality in patients with ulcerative colitis.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aminosalicylic Acids; Child; Cohort Studies; Colectomy; | 1992 |
Neutrophil-mediated nitrosamine formation: role of nitric oxide in rats.
Topics: Aminosalicylic Acids; Animals; Chronic Disease; Colorectal Neoplasms; Inflammation; Male; Mesalamine | 1992 |
1989 Henry Baker lecture. Inflammatory bowel disease: back to the future.
Topics: Adrenal Cortex Hormones; Aminosalicylic Acids; Awards and Prizes; Colorectal Neoplasms; Gastroentero | 1990 |